Tissue Repair Builds Momentum Towards April FDA Submission

Phase III Trial Reaches 112 Patients

Tissue Repair Limited (ASX:TRP) has taken its US chronic wound program to approximately 112 randomised patients, keeping recruitment open as it pursues a potential medical device route alongside the existing Phase III development plan. The trial has moved forward from the 100-patient Phase III update, which reported 100 randomised patients and an October 2026 FDA submission target.

That regulatory timing has now shifted. Tissue Repair is targeting an April 2027 submission for a US FDA 510(k) application, after completing verification and validation work and assembling supporting reports covering chemical characterisation, biological evaluation and packaging integrity. The company estimates approval could take six to 12 months, but the submission and approval dates remain targets rather than regulatory outcomes.

Device Pathway Gains Commercial Importance

The attraction of the device pathway is both regulatory and financial: Tissue Repair describes it as a potentially faster and lower-cost alternative to seeking a new drug approval, which would not require the full Phase III patient recruitment plan. The company also points to US reimbursement changes introduced in April 2026, which it says indicate potential reimbursement of approximately US$1,270 per 10g tube in wound clinic settings. That figure is a potential reimbursement level, not reported revenue.

In Australia, TR Pro+ is now available in 10g, 30g and 200g professional back-bar formats following the first commercial GMP production run. Tissue Repair has resumed direct distribution to aesthetic clinics while maintaining medical-channel distribution, with the company describing early sales results as promising. Its longer-term plan is to pursue the larger global acute wound market following medical device approval.

Cash Supports Trial and Commercial Push

Cash stood at $4.740 million at 30 September, helped by receipt of a $1.940 million FY25 R&D Tax Incentive refund on 1 July. Net operating cash outflow for the quarter was only $19,000 after that receipt, but underlying operating outflow was $1.959 million, broadly comparable with the $1.848 million recorded in the June quarter.

Research and development absorbed $1.055 million, including approximately $978,000 tied to the Phase III program, manufacturing and operating costs were $320,000, and staff costs were $312,000. The company expects a further FY26 R&D refund of about $2.2 million after lodging its tax return, although that amount remains subject to processing.

Buy-Back Proceeds Alongside Manufacturing Scale-Up

Shareholders approved the removal of Tissue Repair from the ASX official list and an off-market equal-access buy-back of up to $1 million at $0.13 a share on 18 September. The offer opened on 29 September and closed on 27 October, with payment expected around 30 October. The move follows the ASX delisting buy-back proposal, which was subject to shareholder approval and was linked to the company’s concerns about liquidity and listing costs. The buy-back is funded from existing cash and was not included in the September quarter cash flows.

On manufacturing, Tissue Repair has procured a second-hand centrifuge intended to accelerate pilot active pharmaceutical ingredient production while reducing capital expenditure. Commercial terms with the contract manufacturer have been agreed, but the manufacturing supply and GMP agreements remain under review, and the equipment’s shipment timing is still to be confirmed after replacement components are installed.